Esophageal cancer (OC) is a leading global malignancy with a poor prognosis; the source reports a 5-year survival rate of approximately 10%–20%. The primary risk factor for esophageal adenocarcinoma (OAC) is the development of Barrett's Esophagus (BO). Despite high clinical importance, the molecular events that drive BO and subsequent progression to OC are not fully defined.
This review synthesizes the evolving epigenetic landscape of esophageal cancer with an emphasis on BO as the precursor lesion. Of the epigenetic mechanisms, DNA methylation is highlighted as the most extensively researched and is the principal focus. The authors examine DNA methylation-associated alterations implicated in both OAC and esophageal squamous cell carcinoma (OSCC), consider disrupted biological pathways, and evaluate the translational potential of methylation-based biomarkers.
Recent studies have identified aberrant DNA methylation patterns in BO and OC. These methylation alterations are associated with both the initiation of neoplastic change and disease progression. The review collates data linking methylation changes to gene regulation in the esophageal epithelium, and emphasizes that epigenetic dysregulation has emerged as a critical area for identifying diagnostic, prognostic, and therapeutic biomarkers. Specific gene-level details, frequencies, or quantitative methylation measures were not reproduced in the abstract and therefore are not reported here.
The review specifically notes that epigenetically regulated genes influence canonical oncogenic pathways implicated in esophageal carcinogenesis. Among these, disruption of Wnt signaling and perturbation of cell cycle control are discussed as mechanisms by which methylation changes may promote malignant transformation and progression. The abstract indicates these pathways are central to understanding how methylation-mediated gene regulation contributes to OC pathogenesis.
A primary translational aim highlighted by the authors is the use of DNA methylation alterations as clinical biomarkers. Methylation markers are considered for: early detection of malignant transformation within BO populations, prognostic stratification of patients with established OC, and risk assessment to identify BO patients at higher likelihood of progression. The review frames methylation-based biomarkers as promising but notes that their clinical utility requires further validation. Precise candidate markers and validation outcomes are not specified in the abstract.
The review underscores caveats inherent to existing literature on epigenetics in BO and OC. While the abstract does not enumerate all limitations, it emphasizes that the molecular pathogenesis is still incompletely understood and that challenges exist in translating epigenetic findings into clinical tests. Typical methodological concerns in the field—such as cohort heterogeneity, technical variability in methylation assays, and need for longitudinal validation—are implied as areas requiring attention, although specific issues are not itemized in the abstract.
The authors conclude by outlining future research needs to advance the field. Key priorities include deeper interrogation of epigenetic mechanisms in BO-to-OC progression, validation of methylation biomarkers for early detection and prognosis, and integration of epigenetic data with other molecular and clinical datasets to improve risk stratification. The review positions epigenetic research as having the potential to enhance mechanistic understanding of OC pathogenesis and to improve patient outcomes, contingent on addressing current challenges.
In summary, the reviewed literature positions epigenetic dysregulation, and notably DNA methylation, as central to contemporary efforts to understand and manage Barrett's Esophagus and esophageal cancer. Methylation alterations affect pathways including Wnt signaling and cell cycle control and hold promise as diagnostic and prognostic biomarkers. However, the molecular basis of BO and OC remains incompletely elucidated and additional rigorous research is required to translate epigenetic discoveries into clinically actionable tools.
Note: This summary is based on the abstract and bibliographic information of the 2026 review (Genes, Chromosomes and Cancer; PMID 42671081; DOI 10.1002/gcc.70167). Detailed study-level data, specific gene names, quantitative methylation findings, and methodological specifics were not provided in the abstract and therefore are not reported here.